Internal Medicine · General Practice ·
Sedative-hypnotic use linked to osteoporosis and fractures in NHANES analysis
A cross-sectional analysis of 44,331 US adults found associations between reported sedative-hypnotic use and higher odds of osteoporosis and fractures. Associations varied by drug class and increased with reported duration of use, but the study cannot establish whether medication use preceded these outcomes.
- Analysis included 44,331 US adults across NHANES cycles.
- Osteoporosis associations differed by sedative-hypnotic class.
- Fracture associations were reported for Z-drugs and benzodiazepines.
- Cross-sectional findings cannot establish causation or temporal order.
Researchers analyzed eight NHANES cycles from 1999–2020, including 44,331 adults aged 20 years or older. Prescription use of benzodiazepines, Z-drugs and barbiturates was self-reported. Osteoporosis was defined using femoral-neck DXA T-scores or a reported physician diagnosis; fractures were self-reported hip, wrist or spine fractures following a fall from standing height or less. Adjusted logistic regression assessed associations with these outcomes and with duration of use.
Use was associated with higher odds of osteoporosis: the reported odds ratios were 2.57 for barbiturates (95% CI 1.09–6.07), 1.93 for Z-drugs (1.44–2.59) and 1.36 for benzodiazepines (1.12–1.63). For fractures, odds were higher with Z-drugs (OR 1.89, 1.11–3.19) and benzodiazepines (OR 1.53, 1.11–2.12). Osteoporosis odds increased by 3% per year of use; the authors also reported a 30% relative increase in fracture probability over 10 years.
The cross-sectional design limits conclusions about timing and causation. Medication exposure and outcomes were based partly on self-report, and the authors call for longitudinal and mechanistic studies. The findings indicate associations, not that sedative-hypnotics directly cause skeletal changes.
In practice
For adults taking benzodiazepines or Z-drugs, this study reports associations with higher odds of self-reported fragility fractures; sedative-hypnotic use was also associated with osteoporosis. These findings may inform awareness of potential skeletal and fall-related concerns, but they do not establish that the medications caused the outcomes or that stopping or changing treatment would reduce risk. The cross-sectional design, self-reported exposure and outcomes, and lack of temporal ordering mean the results do not justify a treatment change on their own.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Osteoporosis International: Sedative-hypnotic use and its association with osteoporosis and fractures: a national analysis, 1999–2020 ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.